Novo Nordisk, the Danish-based healthcare company, has published its 2007 Annual Report on the company’s financial, social and environmental performance. The report is available for download and ordering at www.annualreport2007.novonordisk.com
The printed report comes in two sections: A 50-pages business review and the consolidated financial and non-financial statements.
The online universe offers more detail on sustainability programmes and interactive environmental and social data. This year, Novo Nordisk has chosen to adopt the G3 Sustainability Reporting Guidelines and declares its reporting level as A+.
The report accounts for Novo Nordisk’s way of doing business – its Triple Bottom Line governance structure and values-led approach – and presents achievements during the year as well as challenges ahead. Kicking off with an outline of the company strategy, key risks and mitigating actions, feature articles explore in more depth how Novo Nordisk aims to stay on its ambitious growth course and build on its sustainable business model.
Highlights include a discussion of industry challenges, an account of the company’s activities to deliver on its brand promise Changing Diabetes® and a case story on the business in China.
Novo Nordisk has chosen to develop an integrated reporting format which presents business performance and sustainability-driven initiatives as intertwined. Readers seeking detailed information on issues from advocacy to workplace quality are referred to the website.
Novo Nordisk values stakeholders’ views and welcomes any questions or comments. Please send to [email protected]. Feedback on this report can be left via the CorporateRegister.com listing here.
Novo Nordisk is a focused healthcare company headquartered in Denmark. With 26,000 employees in 80 countries, market presence in 179 countries and R&D and production facilities spanning five continents, the company’s global reach is expanding. Novo Nordisk is a world leader in diabetes care and has leading positions within haemostasis management, growth hormone therapy and hormone replacement therapy.
The report accounts for Novo Nordisk's way of doing business - its Triple Bottom Line governance structure and values-led approach - and presents achievements during the year as well as challenges ahead